Theravance Biopharma, Inc. (TBPH) Financials

TBPH Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 472.3 million 181.7 million
Dec. 31, 2025 485.6 million 188.8 million
Sept. 30, 2025 415.5 million 182.8 million
June 30, 2025 426.0 million 201.2 million

TBPH Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 73.3 million ?
Dec. 31, 2025 -6.1 million 4.5 million
Sept. 30, 2025 -6.5 million 4.6 million
June 30, 2025 208.0 million 4.5 million

TBPH Net Income

No data available :(

TBPH Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 394.7 million 32.8 million 29.8 million
Dec. 31, 2025 315.4 million 32.8 million 31.8 million
Sept. 30, 2025 329.7 million - 44.6 million
June 30, 2025 338.8 million - 46.5 million

TBPH Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 51.3 million
Dec. 31, 2025 53.1 million
Sept. 30, 2025 51.9 million
June 30, 2025 50.7 million

TBPH Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 5.8 million 17.7 million -
Dec. 31, 2025 8000 7.0 million 19.9 million -
Sept. 30, 2025 - 8.1 million 18.3 million -
June 30, 2025 34000 10.5 million 18.4 million -

TBPH Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 17.7 million 1.4 million
Dec. 31, 2025 45.9 million 1.5 million
Sept. 30, 2025 20.0 million 8.1 million
June 30, 2025 26.2 million 10.5 million

TBPH Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TBPH

Price: $16.29

52 week price:
10.42
21.03

Payout Ratio Range:
-661.83%
-457.78%

Earnings Per Share: 2.23 USD

P/E Ratio: 7.41

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: Cayman Islands

Volume: 260600

Ebitda: -62.9 million

Market Capitalization: 803.2 million

Links: